Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899375 | 0.87 | CHEK2 (0.39) | MAOBSLC6A2SLC6A4CHEK2PARP10 | |
| SCHEMBL17899370 | 0.85 | PDE4D (0.39) | ICAM1SELEMAOBSCN9AOPRK1 | |
| SCHEMBL17888686 | 0.85 | ICAM1 (0.38) | ICAM1SELEMAOBSCN9ASLC6A2 | |
| SCHEMBL17888567 | 0.84 | OPRK1 (0.39) | ICAM1SELESCN9AOPRK1OPRM1 | |
| SCHEMBL17899402 | 0.82 | KDM4E (0.42) | ICAM1SELEPARP10SMN1; SMN2KDM4E | |
| SCHEMBL17899369 | 0.80 | SLC6A2 (0.38) | SLC6A2SLC6A4CHEK2OPRK1OPRM1 | |
| SCHEMBL17888545 | 0.77 | KDM4E (0.39) | MAOBSCN9AEPHX2SMN1; SMN2PDE4D | |
| SCHEMBL17899157 | 0.74 | PDE4D (0.39) | OPRK1OPRM1OPRD1PDE4D | |
| SCHEMBL17888565 | 0.73 | LIPG (0.39) | MAOBSCN9ASLC6A2SLC6A4CHEK2 | |
| SCHEMBL21697477 | 0.73 | PARP10 (0.54) | ICAM1SELEMAOBSCN9ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| EP-3607944-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | ICAM1 4383/4885SELE 4603/4885MAOB 595/4885 |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | CCNI, CDK9, CDK8 | ICAM1 3764/4885SELE 3934/4885MAOB 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.